---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-110788"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2023-10-23T23:59:59+00:00"
generated_at: "2026-06-09T16:54:40.094711+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NRX Pharmaceuticals receives Nasdaq delisting notice for bid price non-compliance; plans hearing

## Summary
- Received Nasdaq delisting notice Oct 17, 2023 for failing minimum bid price rule (closing bid <$1 for 30 days).
- Plans to request hearing before Nasdaq Hearings Panel; hearing request will stay delisting pending decision.
- Initial 180-day compliance period expired Oct 16, 2023 without regaining compliance.
- Identifies four potential positive business developments that could affect share price, including NRX-101 trial data and milestone.
- No assurance of Panel decision or ability to regain listing compliance within any extension.

## SEC filing metadata
- accession: 0001104659-23-110788
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2023-10-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465923110788/0001104659-23-110788-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465923110788/tm2328933d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-110788
- JSON: https://secwatch.observer/filing/0001104659-23-110788.json
- Plain text: https://secwatch.observer/filing/0001104659-23-110788.txt

## Key facts
- Listing & Compliance Notices
  NRX Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: October 17, 2023, NRx Pharmaceuticals, Inc. (the “Company”) received formal notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”), the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923110788/0001104659-23-110788-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.